Cogent Biosciences (COGT) Expected to Release Earnings on Friday

Cogent Biosciences (NASDAQ:COGT) is anticipated to announce its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect the company to post earnings of ($0.5573) per share and revenue of $0.75 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, November 9, 2026 at 12:30 PM ET.

Cogent Biosciences (NASDAQ:COGT) last announced its quarterly earnings data on Monday, August 10th. The technology company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.03. On average, analysts expect Cogent Biosciences to post ($2.23) EPS for the current fiscal year and ($1.27) EPS for the next fiscal year.

Cogent Biosciences Stock Performance

NASDAQ:COGT opened at $31.49 on Thursday. The business has a 50 day moving average of $32.08 and a 200 day moving average of $35.60. The company has a market capitalization of $5.46 billion, a price-to-earnings ratio of -14.58 and a beta of 0.36. Cogent Biosciences has a 1-year low of $13.78 and a 1-year high of $43.73. The company has a debt-to-equity ratio of 0.48, a current ratio of 13.57 and a quick ratio of 13.57.

Analysts Set New Price Targets

Several research firms recently issued reports on COGT. Piper Sandler raised their price target on Cogent Biosciences from $52.00 to $55.00 and gave the stock an “overweight” rating in a research report on Monday, August 17th. Guggenheim upped their price target on shares of Cogent Biosciences from $45.00 to $52.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. HC Wainwright reissued a “buy” rating and set a $55.00 price target on shares of Cogent Biosciences in a research report on Tuesday, September 15th. Wall Street Zen lowered shares of Cogent Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, September 5th. Finally, Wedbush reaffirmed an “outperform” rating and set a $55.00 price objective on shares of Cogent Biosciences in a research note on Wednesday, September 16th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Cogent Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.56.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc is a clinical-stage biotechnology company focused on developing precision medicines for genetically defined diseases. The company uses molecular biology and drug-discovery technologies to design therapies intended to target disease-driving mutations while limiting activity in healthy tissues.

Cogent’s lead product candidate is bezuclastinib, also known as CGT9486, an investigational, highly selective inhibitor of the KIT D816V mutation. The company is developing bezuclastinib for systemic mastocytosis, a rare disorder involving the abnormal accumulation of mast cells, including both indolent and advanced forms of the disease.

Cogent conducts its research and clinical-development activities primarily in the United States and works with clinical centers and research partners in support of its development programs.